Peptides DB
Research-centric peptide and protocol reference hub
Study 7 of 9Hexarelin literatureeuropepmc · Animal study · Preclinical2026

Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.

GHRP-6 may have cardioprotective effects in a rat model of myocardial infarction, but further research is needed to determine its relevance to human health.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the hexarelin corpus
4
Preclinical · this one
5
Observational
0
Open-label
0
Randomised
0
Reviews

Summary and findings

This study investigated the effects of GHRP-6 on post-infarct ventricular remodeling and systolic dysfunction in a rat model of permanent coronary artery ligation. The treatment was administered at a dose of 0.4 mg/kg for 7 days following surgery. Results indicated improvements in myocardial tissue integrity and left ventricle physiology.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.Preclinical2026

Abstract

The authors’ words, as europepmc supplied them

<b>Background/Objective</b>: GHRP-6 is a GH secretagogue hexapeptide with expanding and promising cardioprotective effects. Having determined 0.4 mg/kg as the minimum effective dose for enhancing inotropy based on echocardiographic parameters in healthy rats, we implemented a non-reperfusion myocardial infarct model, with its consequent left ventricle wall thinning and ballooning, via permanent left descending coronary artery ligation. <b>Methods</b>: Rats were assigned to three groups: sham-operated/normal rats, infarcted + saline-treated control rats, and infarcted + GHRP-6-administration rats. Treatments were initiated post-surgery and continued for 7 days. On day 7, the animals were echocardiographically and histologically evaluated. For mitochondrial proteomic analysis, an additional 12 healthy rats were used. Six animals received GHRP-6 or normal saline and were observed for 6 h after the inoculation. <b>Results</b>: Here, we show that GHRP-6 attenuated myocardial tissue demise, reduced myocardial interstitial fibrosis/scarring, and integrally improved left ventricle physiology. The proteomic analysis indicated that the GHRP-6 cardioprotective effects may be theoretically mediated by the concerted upregulation of proteins/pathways involved in fatty acid beta-oxidation, apoptosis prevention pathways, antioxidant defenses, and mitochondrial metabolic reprogramming. <b>Conclusions</b>: GHRP-6 is a potent cardioprotective candidate attenuating morphological and functional outcomes caused by late ischemia.

Elsewhere in the Hexarelin corpus

CGHSR agonism increases blood glucose but delays food intake in GHSR hyperresponsive rats.europepmc · 2026 · n=30 · Not reported in abstract.AnimalCHexarelin promotes the survival of retinal ganglion cells after optic nerve transection.europepmc · 2026 · Survival rates of RGC in saline, 25 μg/kg, 50 μg/kg, and 100 μg/kg hexarelin-treated hamsters were 51.2%, 62.4%, 68.5%, and 74.6%, respectively, in 7 days ONT.AnimalBInvestigating the impact of COVID-19 on performance and image enhancing drug usebiorxiv-preprint · 2021 · 45% reported a change in PIED use during lockdown, n=27.HumanCHexarelin promotes the survival of retinal ganglion cells after optic nerve transection.PubMed · 2026 · Survival rates of RGCs were 74.6% at 100 μg/kg hexarelin after 7 days ONT.AnimalDSemantic Scholar search for HexarelinSemanticScholar · 2010CRevealing the interaction between peptide drugs and permeation enhancers in the presence of intestinal bile salts.PubMed · 2023 · Not reported in abstract.In vitro